Drug network derived from the core EGFR interactome and combination strategy to overcome the resistant cells. Drug network derived from the core EGFR interactome.

Slides:



Advertisements
Similar presentations
Table S1. Hypoxia increases signaling through JNK in colon cancer cell lines in a cell-specific manner Shown are the ratios of c-Jun phosphorylation during.
Advertisements

A B Supplementary Figure 1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in.
Supplementary Table S1. List of chemical inhibitors utilized in the current study. Supplementary Information.
Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.
From: Light Induces Programmed Cell Death by Activating Multiple Independent Proteases in a Cone Photoreceptor Cell Line Invest. Ophthalmol. Vis. Sci..
Drug concentration (μM)
Network protein vulnerability in EGFR TKI‐resistant cells and specific for EGFR‐mutated cells. Network protein vulnerability in EGFR TKI‐resistant cells.
Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells  Y. Linda Wu, Uday Bhanu.
Shinichi Sakamoto, Steven Schwarze, Natasha Kyprianou  European Urology 
BRD4 expression levels are associated with sensitivity to BET inhibition in NRAS‐mutant melanoma BRD4 expression levels are associated with sensitivity.
Shinichi Sakamoto, Steven Schwarze, Natasha Kyprianou  European Urology 
Mutant EGFR complexes in lung cancer cell lines and immortalized human bronchial epithelial cells. Mutant EGFR complexes in lung cancer cell lines and.
Experimental confirmation of in vitro GPCR activity of compounds and their scaffolds screened from a chemical library. Experimental confirmation of in.
by Pascal Gelebart, Mona Anand, Hanan Armanious, Anthea C
Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to.
DNA damage induces complex signal activation dynamics across many signaling pathways. DNA damage induces complex signal activation dynamics across many.
S55746 synergizes with panobinostat in vitro and in vivo in DLBCL
A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.
The impact of the IGF-1 system of cancer cells on radiation response – An in vitro study  Senthiladipan Venkatachalam, Esther Mettler, Christian Fottner,
(C–F) Complete interaction networks (representing both baits and preys) for selected groups of baits. (C–F) Complete interaction networks (representing.
Thermal profiling identifies kinases involved in PI3K/AKT/mTOR signaling and glycolytic metabolism as palbociclib targets Thermal profiling identifies.
Luminex phosphorylation measurements are reproducible and have broad dynamic range Individual difference in insulin‐induced phosphorylation of ERK measured.
The human STRIPAK complex associates with RASF3 and MST1/2
Synergistic effect of S63845 with lapatinib, trastuzumab, or docetaxel
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism by Piro Lito, Martha Solomon, Lian-Sheng Li, Rasmus Hansen, and Neal Rosen.
Volume 19, Issue 7, Pages (July 2012)
Volume 19, Issue 9, Pages (September 2017)
AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer  Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,
WZ4003, a specific NUAK1 and NUAK2 inhibitor (A) Chemical structure of the NUAK1/NUAK2 inhibitor WZ4003. WZ4003, a specific NUAK1 and NUAK2 inhibitor (A)
Volume 22, Issue 3, Pages (March 2015)
BRD4 expression levels are associated with sensitivity to BET inhibition in NRAS‐mutant melanoma BRD4 expression levels are associated with sensitivity.
SEMA3C silencing inhibits CRPC cell growth and induces apoptosis
Figure 1. A CRISPR/Cas9 synthetic lethal screen with PRMT5 inhibitor EPZ in H2171 cell line. (A) A pie chart ... Figure 1. A CRISPR/Cas9 synthetic.
The Selective Protein Kinase C β Inhibitor Enzastaurin Induces Apoptosis in Cutaneous T-Cell Lymphoma Cell Lines through the AKT Pathway  Christiane Querfeld,
MITF upregulation leads to Hsp90i resistance
Inhibition of CDK6 kinase activity sensitizes EOC cells to platinum in vitro Inhibition of CDK6 kinase activity sensitizes EOC cells to platinum in vitro.
Physical EGFR interactome generation and core network proteins identification. Physical EGFR interactome generation and core network proteins identification.
Volume 18, Issue 11, Pages (November 2011)
Dynamic changes of protein phosphorylation identify ERK1/2 substrates from cytosolic and nuclear compartments. Dynamic changes of protein phosphorylation.
Volume 19, Issue 12, Pages (December 2012)
Chemical inhibitors of microtubule function attenuate signal but do not affect pathway variability Chemical inhibitors of microtubule function attenuate.
Volume 16, Issue 24, Pages (December 2006)
48 clinically relevant GPCR receptors mapped using MYTH
Schedule-Dependent Interaction between the Proteosome Inhibitor Bortezomib and the EGFR-TK Inhibitor Erlotinib in Human Non-small Cell Lung Cancer Cell.
Fig. 3. TKI sensitivity assessed by the MANO method.
An integrated NHR network.
TIMP-2 Mediated Inhibition of Angiogenesis
Molecular Therapy - Nucleic Acids
Melting behavior of protein complexes
UA62784 Is a Cytotoxic Inhibitor of Microtubules, not CENP-E
Global and focused views of human interaction map.
Shu complex condition‐dependent genetic interactions with MAG1, SLX4, PPH3, and RAD53 Shu complex condition‐dependent genetic interactions with MAG1, SLX4,
A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.
Growth of TKI‐resistant EGFR delE746‐A750 PC‐9 NSCLC cells is associated with elevated cellular free fatty acid and expression of FASN, and is suppressed.
Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol. Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol.
Nilotinib inhibits DDR1 invasive activity of patient‐derived CRC cells
The oligoclonal antibody overcomes the C797S mutation‐mediated resistance to osimertinib The oligoclonal antibody overcomes the C797S mutation‐mediated.
CEP55 is a downstream effector of MAPK signaling
Volume 18, Issue 11, Pages (November 2011)
MEL23 and MEL24 inhibit Mdm2 and p53 ubiquitination through the Mdm2-MdmX hetero-complex. MEL23 and MEL24 inhibit Mdm2 and p53 ubiquitination through the.
Cell viability assay and expression of COX protein.
Activity of SW480 qHTS runs and podophyllotoxin titration–response profiles of from library and control samples. Activity of SW480 qHTS runs and podophyllotoxin.
Identification of NSC as a FADD-kinase inhibitor.
CDs with KRASG12C cooperatively sustain downstream signaling outputs to promote survival and proliferation. CDs with KRASG12C cooperatively sustain downstream.
Volume 65, Issue 5, Pages e4 (March 2017)
Quantitative PTEN protein expression is associated with pertuzumab sensitivity in vitro and trastuzumab resistance in vivo. Quantitative PTEN protein expression.
RA-9 induces G2–M cell-cycle arrest and caspase-mediated apoptosis in ovarian cancer cells. RA-9 induces G2–M cell-cycle arrest and caspase-mediated apoptosis.
THZ1 in combination with targeted therapy enhances cell death and hinders the establishment of drug-resistant colonies in diverse oncogene-addicted cellular.
A, Pharmacologically inhibiting protein tyrosine kinases significantly reduces the viability of ATRT cell lines as compared with control HEK 293 cells.
Afatinib rapidly destabilizes endogenous TRIB2 and specifically induces caspase 3 cleavage and U937 cytotoxicity. Afatinib rapidly destabilizes endogenous.
Presentation transcript:

Drug network derived from the core EGFR interactome and combination strategy to overcome the resistant cells. Drug network derived from the core EGFR interactome and combination strategy to overcome the resistant cells. (A) Blue rectangles indicate core network proteins (N=14), and 1520 red hexagon nodes represent compounds. Orange lines between drug and protein indicate the relationships derived by the literature‐reported interactions. (B) Kinase inhibitors derived from competition binding assays were integrated to the core network. Blue nodes=EGFR‐specific core proteins for cell survival and red nodes=non‐specific core proteins in the EGFR interactome; rectangles=baits; ellipses=prey or protein identified by phosphoproteomics; orange lines=binding interactions between the inhibitor and the particular protein. The inhibitors are indicated by hexagons, with colors related to Kd shown at bottom right. (C) In vitro kinase assay results using purified EGFR kinases from indicated alleles were assessed after incubation with indicated concentration of midostaurin. Kinase activity results are shown as a percentage compared to DMSO control. (D) Lysates from either PC9 or PC9GR cells were incubated with immobilized midostaurin, and unique peptides corresponding to EGFR or other validated midostaurin target proteins (AMPK1α and PDPK1) were quantified. Number of unique peptides is shown for each protein. (E) The cells were exposed to erlotinib (Erlo), midostaurin (Mido), or combination at indicated concentrations. Signaling changes were evaluated by western blotting after 4 h treatment. (F) Indicated cells, including H157 cells with wild‐type EGFR, were treated with 500 nM erlotinib, 1000, nM midostaurin, 500 nM CEP‐701, or combination with erlotinib at the same concentration for 24 h. PARP cleavage was evaluated by western blotting (left panel) and caspase 3 activity measured by flow cytometry (right panel) are means±s.d. for triplicate data points. ‘**’: P<0.01; ‘*’: P<0.05 comparing combination treatment with other single treatment. In (E and G), equal protein loading was confirmed by β‐actin evaluation. (G) Cells were exposed to titration concentration of erlotinib, midostaurin, and combination of erlotinib with midostaurin or (H) Cells were exposed to titration concentration of erlotinib, CEP‐701, and combination of erlotinib with CEP‐701 at the same rate concentrations. The cell viability was assessed by CellTiter Glo after 5‐day treatment. The growth curves were constructed by GraphPad Prism 6 and combination index (CI) was calculated by the CompuSyn software ( http://www.combosyn.com/). CI<1 represents synergism in drug combinations and was labeled below the curve of combination group. Jiannong Li et al. Mol Syst Biol 2013;9:705 © as stated in the article, figure or figure legend